InVivoMAb Anti-SARS-CoV-2 RBD (KP.2 variant) Neutralizing Antibody (Iv0262) (VK565150)

Name: InVivoMAb Anti-SARS-CoV-2 RBD (KP.2 variant) Neutralizing Antibody (Iv0262)
Brand: abinScience
SKU: VK565150
Price: 370 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

100ug
1mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер	VK565150
Описание	InVivoMAb Anti-SARS-CoV-2 RBD (KP.2) Neutralizing Antibody (Iv0262) [Iv0262] (VK565150) is a human monoclonal antibody detecting Spike glycoprotein in ELISA, Neutralization.
Реактивность видов	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Применения	ELISA, Neutralization
Хозяинский вид	Human
Клоональность	Monoclonal
Изотип	IgG1
ID клона	Iv0262
Цель	Spike glycoprotein, Spike, S glycoprotein, RBD
Уровень эндотоксинов	< 1 EU/mg
Чистота	>95% as determined by SDS-PAGE.
Очистка	Protein A/G purified from cell culture supernatant.
Номер доступа	P0DTC2
Форма	Liquid
Буфер хранения	0.01M PBS pH 7.4. Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.
Устойчивость и хранение	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Фон	Spike glycoprotein (RBD (Omicron/KP.2)) is a ~141 kDa protein. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2. When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane. When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis using host TFRC and GRM2 and leading to fusion of the virion membrane with the host endosomal membrane. Alternatively, may use NRP1/NRP2 and integrin as entry receptors. 1. Hoffmann, M. et al. (2020) Cell 181, 271-280.e8. PMID: 32142651 2. Walls, AC. et al. (2020) Cell 181, 281-292.e6. PMID: 32155444 3. Cao, W. et al. (2021) Biophysical journal 120, 1011-1019. PMID: 33607086 4. Takeda, M. (2022) Microbiology and immunology 66, 15-23. PMID: 34561887 5. Wrapp, D. et al. (2020) Science (New York, N.Y.) 367, 1260-1263. PMID: 32075877 6. Ou, X. et al. (2020) Nature communications 11, 1620. PMID: 32221306 7. Wang, J. et al. (2021) Cell discovery 7, 119. PMID: 34903715 8. Wang, X. et al. (2023) Journal of virology 97, e0161122. PMID: 36779763 9. Daly, JL. et al. (2020) Science (New York, N.Y.) 370, 861-865. PMID: 33082294 10. Cantuti-Castelvetri, L. et al. (2020) Science (New York, N.Y.) 370, 856-860. PMID: 33082293
Примечание	For research use only. Not suitable for clinical or therapeutic use.